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Vagus nerve stimulation (VNS) is an adjunctive antiepileptic treatment for patients with refractory epilepsy. Limited information
on long-term treatment with VNS is available. The purpose of this paper is to present our experience with VNS with a follow-up
of up to 4 years.
Twenty-five patients (13 females and 12 males) with refractory partial epilepsy were treated with VNS. The first 15 patients
with a mean age of 30 years and a mean duration of epilepsy of 17.5 years have sufficient follow-up for analysis.
Mean post-implantation follow-up was 29 months and mean stimulation output 2.25 mA. There was a mean seizure frequency
reduction from 14 complex partial seizures (CPS) per month before implantation to 8 CPS per month after implantation (P =
0.0016; Wilcoxon signed-rank rest (WSRT)). The mean maximum CPS-free interval changed from 9 to 312 days (P = 0.0007;
WSRT). Six patients were free of CPS for at least one year. In one patient, one antiepileptic drug (AED) was tapered; in
10 patients, AEDs remained unchanged; in four, one adjunctive AED was administered. Side effects occurred in six patients,
three of whom required a temporary reduction of output current. Nine patients reported no side effects at all.
Treatment with VNS remains effective in the long-term. In this series 4/15 (27%) patients with highly refractory epilepsy
experienced entirely seizure-free intervals of 12 months or more.
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seizure-free.INTRODUCTION
Approximately 1% of the population suffers from
chronic epilepsy. Partial epilepsy is the most common
type of epilepsy in adults1. According to the litera-
ture, about 20% of patients with epilepsy have uncon-
trolled or poorly controlled seizures despite adequate
treatment with antiepileptic drugs (AEDs)2. For these
patients, epilepsy surgery may represent a therapeu-
tic alternative. This requires a thorough patient selec-
tion and only 30–50% of patients can be operated on
after extensive pre-surgical evaluation3. Implantation
with a vagus nerve stimulator is a novel and currently
available antiepileptic treatment modality for the re-
maining patients. Worldwide, more than 3500 patients
have been implanted and several mostly short-term
studies on efficacy and safety have been published4–8.
The current consensus is that a third of patients expe-1059–1311/99/060328 + 07 $12.00/0rience a considerable improvement in seizure control
with a reduction in seizure frequency of at least 50%, a
third of patients experience a worthwhile reduction of
seizure frequency between 30 and 50%. In the remain-
ing third of the patients, there is little or no effect.
Currently limited information is available on pa-
tients with refractory partial epilepsy who be-
came seizure-free during vagus nerve stimulation
(VNS)16, 17. There are no studies that evaluate the clin-
ical, neuroimaging and EEG features of seizure-free
patients treated with VNS. The purpose of this paper
is to evaluate seizure control in 15 implanted patients
with long-term follow-up and to describe in detail the
case reports of three out of four patients who expe-
rienced long-term (≥12 months) entirely seizure-free
intervals.c© 1999 BEA Trading Ltd
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At the University Hospital in Gent, 25 patients
(12 females and 13 males) have been implanted with a
VNS between March 1995 and April 1999. These pa-
tients were part of a larger group (n = 150) of patients
with medically refractory epilepsy who were included
in a pre-surgical evaluation protocol. After video-
EEG monitoring, optimum MRI, interictal FDG-PET
and neuropsychological assessment, 105/150 patients
were found to be unsuitable candidates for resective
surgery. In some patients, a confined and resectable
epileptic zone could not be identified; in others, resec-
tive surgery was contraindicated because of the fear of
a possible post-operative cognitive deficit. These pa-
tients were offered three alternatives: rematching of
standard AEDs, drug-trials with novel AEDs or VNS.
Fifty patients continued their medical treatment and
had a rematching of standard AEDs, 30 patients were
included in phase-3 drug trials with novel AEDs such
as topiramate, gabapentin or levetiracetam. Twenty-
five patients were offered implantation of a vagus
nerve stimulator and gave informed consent. The local
ethics committee approved the VNS implantation and
study protocol. The first 15 patients (6M, 9F) have suf-
ficient follow-up data for analysis and will be further
discussed in this study. Mean follow-up in these 15 pa-
tients was 29 months (range 12–48; SD = 11.9). Six
out of fifteen patients have a follow-up of 1–2 years;
5/15 have a follow of 2–3 years; 4/15 have a follow-
up of 3–4 years. The mean age of these patients was
30 years (range: 17–44 years; SD= 7.9); the mean du-
ration of epilepsy was 17.5 years (range: 5–35 years;
SD = 8.5). All patients but one were on chronic an-
ticonvulsant polytherapy, the mean number of AEDs
being 3 (range 1–4; SD = 0.8).
Stimulation of the left vagus nerve was performed
using the Neurocybernetic Prosthesis (NCPr) Sys-
tem (Cyberonics Inc., Houston Texas) that comprises
two components: the NCPr (a generator which is
implanted subcutaneously in a subclavicular pouch)
and the NCPr-lead with two spiral electrodes that
are wound around the left vagus nerve in the neck.
The surgical procedure, described previously9–11, re-
quires general anaesthesia and takes about 1 hour. Pa-
tients were discharged 24 hours after surgery. Stim-
ulation was initiated within 2–4 weeks after surgery.
The generator was programmed using a portable com-
puter provided with a programming device and spe-
cialized software. The programming device was held
upon the patient’s chest above the implanted generator
to program the various stimulation parameters such as
output current, frequency, pulse-width and on/off pe-
riods. During follow-up clinic visits, the output cur-
rent was gradually ramped up with 0.25–0.50 mA per
visit until individual patient tolerance or a maximumof 3 mA was reached. The other parameters were pro-
grammed according to ‘standard stimulation’ with a
frequency of 30 Hz, pulse width of 500 µs, on/off pe-
riods of 30 s/300–600 s. The patients were also pro-
vided with a magnet allowing additional stimulation
to be commanded by the patient or a bystander in the
case of an aura or seizure. The magnet output current
was programmed at 0.25 mA higher than the auto-
matically delivered stimulation with a pulse width of
500 µs for a period of 30 s. Standard stimulation was
replaced by ‘rapid cycle stimulation’ (on/off periods
= 7 s/14 s) in patients who did not respond to stan-
dard stimulation parameters. This has been shown to
be effective in some patients12. Patients were followed
on an outpatient basis at regular intervals, usually ev-
ery 2–4 weeks during ramping up. Afterwards patients
were seen every 1–3 months for further follow-up. At
every clinic visit, seizure frequency, seizure type, pre-
scribed AEDs and dosage as well as any side effects
of VNS were assessed. In every patient, we prospec-
tively assessed the decrease of seizure frequency in re-
lation to stimulation output current and type (standard
vs. rapid cycle), seizure type(s) suppressed by VNS,
change in duration of seizures, and duration of seizure-
free intervals. Seizure frequency during the year be-
fore and the full follow-up period after the day of im-
plantation was compared using the Wilcoxon signed-
rank test (WSRT). Using the same statistical test, we
also compared the maximum complex partial seizures
(CPS)-free days in the year before VNS and follow-up
time after VNS. Because of difficulties in accountabil-
ity, simple partial seziures (SPS) were not included in
this analysis.
RESULTS
In all 15 patients the surgical procedure was uncom-
plicated and the post-operative period was unevent-
ful. The patients were discharged from the hospi-
tal 24 hours after surgery. After ramping up during
2–4 months, mean stimulation output was 2.25 mA
(range 1.5–3 mA; SD = 0.6). Usually, the occurrence
of coughing and/or an unpleasant sensation in the
throat was the limiting factor for further increasing the
output current.
During follow-up, the patients showed a mean re-
duction in CPS frequency from 14 seizures per month
(range: 2–40 per month; SD = 13.8) to 8 seizures
per month (range: 0–30 per month; SD = 12.1). This
reduction is statistically significant (P = 0.0016;
WSRT). One patient showed clusters of up to 10 CPS
a day (200 seizures per month) and had a clear-cut re-
duction of this seizure frequency. This patient was not
included in the analysis for statistical reasons. Six pa-
tients were free from CPS during a ≥12-month inter-
val. Four our of six patients experienced an entirely
seizure-free interval of 12 months or more. Two out
330 K. Vonck et al.of six patients still have SPS but stopped having CPS
within 3 months after stimulation initiation. Four other
patients had a seizure reduction of more than 50%;
two patients had a worthwhile reduction of seizure
frequency between 30–50%; in three patients, seizure
reduction was less than 30% or seizure frequency re-
mained unchanged.
A reduction in seizure frequency of ≥50% was
achieved within the first 4 months after initiation of
stimulation in 8/10 patients, amongst whom were all
six patients with seizure-free intervals of ≥12 months.
At the time of evaluation, 6/13, who frequently had
secondary generalized tonic–clonic seizures before
implantation, were free of convulsions. Five out of
seven patients who still experience secondary gener-
alization have had a ≥50% reduction in frequency
and/or duration of convulsions.
The mean maximum complex partial seizure-
free interval changed from 9 days (range: 1–
30 days; SD = 8.1) to 312 days (range: 3–1430 days;
SD = 469.1). This change in seizure-free interval is
statistically significant (P = 0.0007; WSRT). Patients
with a ≥50% reduction of seizure frequency had a
mean pre-implantation seizure frequency of 5.9 vs. 13,
7 (n.s.; P = 0.0646) in the total population. The num-
ber and average dosage of AEDs remained unchanged
in 10 patients. In one patient, tapering of two AEDs re-
duced polytherapy but in four patients one adjunctive
AED had to be administered. Three out of four pa-
tients that are currently free from all types of seizures
never had any change of AED treatment. One out of
four had a trial with vigabatrin and later on with lam-
otrigine. Two patients who are free from CPS but still
experience SPS had trials with novel AEDs without
additional benefit regarding the occurrence of SPS.
At the first stimulation with 0.25 mA output current,
almost all patients reported a funny and indescrib-
able sensation in the throat, as if they were to swal-
low. Each time the output was gradually increased,
this sensation reoccurred and subsided spontaneously
within 48 hours. This throat sensation was considered
a minor and intrinsic side effect causing no pain or
real discomfort.
Six patients reported true side effects. Two of these
patients complained of mild intermittent hoarseness or
voice alteration during stimulation and one patient ex-
perienced dysphagia at the time of stimulation. These
side effects did not require any change of stimula-
tion output and subsided over a time period of several
weeks. However, three patients reported persistent
coughing and additional unpleasant chest, throat or
neck sensations during the ramping-up period. This
required a temporary reduction of the output current
but none of the patients requested that the stimulation
be turned off. Nine patients did not report any side
effects at all.CASE-REPORT # 1
UP is a 36-year-old right-handed male who suffered
from epilepsy since age 11. He had complicated febrile
seizures as a toddler. At age eight, he experienced
a severe head trauma with subsequent coma lasting
4 months. At age 11, he started having CPS con-
sisting of a rising epigastric sensation followed by
impairment of consciousness and semipurposeful be-
haviour. From adolescence on, these seizures fre-
quently evolved into secondary generalization. At the
time of evaluation he had at least two secondary gener-
alized seizures per week. After extensive trials with all
available AEDs in various combinations including vi-
gabatrin and lamotrigine, the patient was evaluated for
epilepsy surgery. Video-EEG monitoring confirmed
the existence of partial seizures with strikingly fast
secondary generalization. Neither were there clinically
lateralizing features, nor could the ictal EEG be lat-
eralized. Interictal EEG showed bilateral independent
epileptic discharges and no consistent focus. Optimum
MRI showed bilateral hippocampal atrophy, more ob-
vious on the right side. FDG-PET revealed widespread
right temporal hypometabolism. Neuropsychological
testing showed a mild mental retardation and severe
psychological instability. The patient was considered
unable to cope with the necessary invasive evaluations
such as intracranial video-EEG monitoring and there-
fore unsuitable for further pre-surgical assessment. In
March 1995, he was implanted with a vagus nerve
stimulator. At that time he was treated with carba-
mazepine and sodium valproate. In the first weeks
during ramping up, he complained of hoarseness at
the time of stimulation. Within 3 months, there was
a reduction of seizure frequency of 50%. Side effects
due to stimulation subsided during further ramping
up. Since September 1996, the output current of the
stimulator has been 2.25 mA. Apart from a tempo-
rary decrease of convulsions, there was no further im-
provement of seizure control despite the initiation of
rapid cycle stimulation. Lamotrigine was added to the
antiepileptic therapy of the patient in February 1997
at an initial dosage of 25 mg a day and was increased
by the same amount every week until reaching a total
dosage of 300 mg bid. Shortly after the administration
of lamotrigine, when he was on 100 mg bid, the patient
became entirely seizure-free. After 12 months of com-
plete seizure-freedom the patient insisted on reducing
lamotrigine. During tapering he had two tonic–clonic
seizures. Therapy was reinstalled and the patient has
remained completely seizure-free since.
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Table 1: Patient characteristics.
Patient no. Initials Sex Age Seizure Duration Follow-up History
(years) (months)
1 UP M 36 22 48 febrile seizures, head trauma
2 VD F 34 5 48 head trauma
3 BI M 39 13 42 head trauma
4 VC F 32 18 40 encephalitis
5 SP M 30 18 35 premature birth, callosotomy
6 HF M 21 18 35 febrile seizures
7 VE M 29 22 34 head trauma
8 BI F 23 18 28 febrile seizures, head trauma
9 JMA F 32 9 25 febrile seizures
10 BJ F 25 23 23 febrile seizures, encephalitis
11 GL F 39 31 20 forceps birth
12 VJC F 44 35 17 meningitis, ventricular atrial drainage
13 MG F 17 11 17 none
14 VS F 25 13 16 none
15 VC M 20 6 12 meningitis, head traumaCASE-REPORT # 2
BI is a 39-year-old right-handed man who developed
epilepsy at age 23. He had a severe head trauma due to
a car accident at age 10. Habitual seizures occurred
weekly and began with a strange and indescribable
feeling with occasional automatisms followed by de-
viation of the patient’s head to the left and elevation of
his left arm. There was loss of consciousness and sub-
sequent secondary generalization. Despite adequate
trials with all available AEDs, there was no reduction
of seizure frequency. At least once a month, the patient
was brought into the emergency room with severe head
trauma due to seizures. While being treated with three
different AEDs, his maximum seizure-free period was
1 week. At the time of evaluation on the monitoring
unit he had four habitual seizures with clinical charac-
teristics suggestive of supplementary motor area on-
set. The ictal EEG showed a right hemispheric epilep-
tic recruitment; interictally there was diffuse slow-
ing. Optimum MRI revealed bilateral hippocampal
signal abnormalities and a left temporal arachnoidal
cyst. PET turned out normal. On neuropsychologi-
cal assessment, the patient presented a disharmonic
profile with a frontal dysfunction but no lateralizing
signs. Because of the discrepancies between the re-
sults of the different pre-surgical tests, the patient was
no longer considered a suitable candidate for resective
surgery. In September 1995, he was implanted with
a vagus nerve stimulator. At the time of implantation
he was treated with carbamazepine, sodium valproate
and vigabatrin. After the operation he became entirely
seizure-free. In June 1996, he experienced a short-
lasting CPS after a quarrel with colleagues at work but
has remained free of seizures since. Stimulation output
current is 1.5 mA. Apart from mild transient hoarse-ness, the patient did not report any side effects. AED
treatment has been unchanged since the implantation.
CASE-REPORT # 3
VJC is a 44-year-old right-handed woman who was
diagnosed with meningitis complicated by a brain
abscess in her right hemisphere at age 8. As a result
she developed a partial hemiparesis of the left side
of her body and recurrent epileptic seizures. Habit-
ual seizures began with an uncomfortable feeling in
her stomach followed by staring and loss of contact
for about two minutes. There was a prolonged postic-
tal period of confusion. Despite treatment with sev-
eral AEDs, she had monthly seizures. Occasionally
the patient experienced secondary generalization dur-
ing night time.
Video-EEG monitoring documented CPS with sec-
ondary generalization. Ictal onset was located in the
right hemisphere but differentiation between tempo-
ral or frontal onset could not be made. Interictally,
there was irregular slow activity on right-sided fronto-
centro-temporal electrodes, but there were no focal
epileptic discharges. MRI showed right hemispheric
porencephaly and gliosis in a large area of the pari-
etal, frontal and temporal lobes on the right side. This
was consistent with FDG-PET findings that revealed
an ametabolic area in the same region surrounded by
a larger hypometabolic area. Because of the extent of
the lesion and difficulty in defining the area of ictal
onset, the patient was no longer considered a suitable
candidate for resective surgery.
She was ultimately implanted with a vagus nerve
stimulator in October 1997. At that time she was
treated with lamotrigine. Stimulation was initiated and
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Table 2: Pre-surgical evaluation.
Patient no. Interictal EEG Ictal EEG MR PET
1 bil independent sharp and sp/w muscle artifact R hipp atrophy R T hypometab
2 R PT theta activity R ictal recruitment R frontal dysplasia R F hypometab
3 R T theta activity Normal L T arachnoidal cyst bil hipp normal
gliosis L > R
4 R TO sp/w bil ictal recruitment normal R T hypometab
5 R T rhytmical theta activity Normal bil frontal signal abn L FP hypometab
6 bil theta & delta activity R ictal recruitment single white matter defect semioval normal
center
7 bil theta activity R T ictal recruitment R hipp and cerebellar atrophy R T hypometab
8 L T theta activity L T ictal recruitment normal L PT hypometab
9 normal R T ictalrecruitment R medial T atrophy R hypometab
10 bil post sharp activity R > L T ictal recruitment L posterior hipp structural B PT hypometab
abnormality
11 R T sp/w L rhythmicity normal bil L > R F hypometab
12 R FT thet & delta activity R FT recruitment R FT porencephaly R PT ametab hypometab
13 R FT spikes R > L anterior recruitment normal bil T hypometab
14 bil post sp/w bil ictal recruitment bil migration disorder sylvian R T hypometab
fissure; polymicrogyri
15 normal RF ictal recruitment F R > L cortical abn gyrus R T hypometab
Notation: bil: bilateral; sp/w: spike and wave; R: right, L: left; PT: parietotemporal; T: temporal; TO: temporooccipital; FT: frontotemporal;
hipp: hippocampal; abn: abnormality; F: frontal; hypometab: hypometabolism.
Table 3: Seizure type, seizure frequency and stimulation output.
Patient Seizure type Mean CPS frequency/mth % reduction in SZ Output (mA)
no. Pre VNS Post VNS Pre VNS Post VNS frequency
1 CPS+ SG / 8 0a >50 2.25
2 CPS± SG/SPS SPS 3 0a >50 2.5
3 CPS± SG / 4 0a >50 1.5
4 CPS± SG CPS± SG 40 25 30–50 2.75
5 CPS± SG/SPS CPS± SG/SPS 4 3 <30 2.5
6 CPS+ SG CPS+ SG 4 1a >50 2.5
7 CPS± SG CPS± SG 30 20 30–50 2
8 CPS± SG/SPS / 4 0 >50 1.5
9 CPS± SG CPS± SG 16 4a >50 2.25
10 CPS± SG CPS± SG 35 30 <30 3
11 CPS± SG CPS 8 2a >50 2.25
12 CPS+ SG / 2 0a >50 1.75
13 CPS± SG/SPS SPS 200(clusters) 1 day of clusters >50 1.5
14 CPS+ atonic CPS+ atonic 30 30 <30 3
15 CPS CPS 4 1a >50 3
aPatients with ≥50% reduction of seizure frequency within 4 months post-implantation.ramped up to an output current of 1.25 mA. Since the
implantation, the patient has been completely seizure-
free and has experienced no side effects.
DISCUSSION
VNS is presently used in patients with severe med-
ically refractory epilepsy who are not surgical can-
didates or who failed resective epilepsy surgery13, 14.
Most implanted patients are adults but a small series
of children have been implanted in the context of clin-
ical trials with results comparable to those obtained
in adults12, 15. In the course of an ongoing antiepilep-
tic treatment, it is not always clear which treatment
changes are responsible for improvement of seizurecontrol. In our center, none of the patients treated
with VNS were included in controlled clinical tri-
als. Hence, adjustment of stimulation parameters and
AEDs were at the discretion of the treating physi-
cian. Due to the open and descriptive design of this
study, the reduction in seizure frequency that was
observed in some patients may represent: (a) a true
effect of chronic VNS with standard stimulation pa-
rameters, (b) an effect of VNS with acute or chronic
rapid cycle stimulation, (c) a synergistic effect be-
tween VNS and AEDs, (d) a reflection of the natural
history of the epilepsy or, (e) more unlikely, a placebo
effect.
There are very few reports in the literature on the
long-term (>2 years) efficacy of chronic VNS16, 17.
Results from these studies indicate that VNS remained
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